In patients who had revascularization after an acute MI and had a preserved EF, long-term beta-blocker use showed no benefit compared with no beta-blockers, in REDUCE-AMI.
In patients with severe hypertriglyceridemia who are at risk for acute pancreatitis, the drug brought about triglyceride reductions of more than 50% in the phase 2 SHASTA-2 study.